14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
CLBR vs BGLC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, BioNexus Gene Lab Corp (BGLC) is the stronger overall head-to-head candidate over CLBR (CLBR) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CLBR carries a Unified Composite Score of 47.5/100 (HOLD) at $10.02 (N/M Forward P/E, N/A operating margin), whereas BGLC carries 44.2/100 (HOLD) at $0.68 (N/M Forward P/E, -88.2% operating margin).
Composite vs. Pillar Nuance: While CLBR currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. BGLC 44.2/100 HOLD), BGLC captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (-88.2% vs. N/A operating margin) and revenue trajectory (-96.6% vs. N/A YoY).
Technical & Structure Timing Caution: CLBR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 35.4); meanwhile BGLC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLBR vs BGLC. Trailing 12-month operating profitability (CLBR N/A vs BGLC -88.2%) and valuation multiples (CLBR N/M vs BGLC N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Specialty Chemicals value chain with $2.0M market capitalization and -88.2% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CLBR vs BGLC Key Questions & Quantitative Answers
As of Nov 20, 2026, BioNexus Gene Lab Corp (BGLC) is the stronger overall head-to-head candidate over CLBR (CLBR) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CLBR carries a Unified Composite Score of 47.5/100 (HOLD) at $10.02 (N/M Forward P/E, N/A operating margin), whereas BGLC carries 44.2/100 (HOLD) at $0.68 (N/M Forward P/E, -88.2% operating margin). Composite vs. Pillar Nuance: While CLBR currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. BGLC 44.2/100 HOLD), BGLC captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–0 across the 6 pillars) due to superior fundamental profitability (-88.2% vs. N/A operating margin) and revenue trajectory (-96.6% vs. N/A YoY). Technical & Structure Timing Caution: CLBR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 35.4); meanwhile BGLC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BGLC leads the Growth & Scale pillar: CLBR posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BGLC at -96.6% YoY revenue growth and -95.0% YoY earnings growth on $3.1M TTM revenue (12.3% gross margin, -88.2% operating margin). On trailing 12-month operating scale, CLBR generates N/A in USD-normalized revenue versus $3.1M for BGLC. In operating R&D and SG&A reinvestment, CLBR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BGLC.
CLBR and BGLC trade at balanced relative valuation multiples. CLBR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BGLC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (-38.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLBR (N/A ROE) versus BGLC (-33.7% ROE) capital efficiency.
In options market volatility and institutional positioning, CLBR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.08β · 4% Vol realized risk). By comparison, BGLC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 86% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.